(2025, April 15)
This guide reviews evidence on post-GLP-1 rebound effects, outlines who may benefit most from tapering, and details sustainable strategies, nutrition, exercise, and sleep, to maintain long-term success
Compounded drugs have not been reviewed by the FDA for safety, efficacy, or manufacturing quality
Tirzepatide (a GLP-1/GIP dual agonist) and oral GLP-1 formulations activate slightly different receptor pathways and produce different gastrointestinal response patterns in some patients
This pill was initially sold under the name Rybelsus, but was rebranded as Ozempic in May 2026
To get FDA approval for Zepbound , Eli Lilly had to prove the drug was safe, effective, and consistently manufactured through large-scale clinical trials (the SURMOUNT program)